February 11, 2020
Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS. Read the Press Release
JANUARY 27, 2020
Biophytis SARA-INT Phase 2b study, evaluating the efficacy of Sarconeos (BIO101) in sarcopenia, has now achieved over 50% patient recruitment. Read the Press Release
JANUARY 10, 2020
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release
JANUARY 2, 2020
Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management Team. Read the Press Release
December 16, 2019
Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with Duchenne Muscular Dystrophy (DMD). Read the Press Release
December 12, 2019
Biophytis to attend Biotech Showcase™ 2020 in San Francisco, USA. Read the Press Release
December 9, 2019
Biophytis Presents Preliminary Analysis of SARA-OBS study at the 12th Annual Congress of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) in Berlin, Germany. Read the Press Release
DECEMBER 4, 2019
Biophytis to attend 11th Geneva MidCap Event. Read the Press Release
NOVEMBER 18, 2019
Biophytis to participate in the 6th China Healthcare Summit organized by BioCentury and BayHelix in Shanghai. Read the Press Release
November 15, 2019
Biophytis Files IND Application with FDA for Sarconeos (BIO101) to Support Planned MYODA Clinical Program in Patients with DMD. Read the Press Release